Marked, Lasting Disease Regression and Concomitantly Induced Autoimmune Hemolytic Anemia and Hemophagocytic Lymphohistiocytosis in a Patient With Lung Adenocarcinoma and Autoantibodies Receiving Atezolizumab Plus Chemotherapy: A Case Report

被引：7

作者：

Endo, Yoshinari ^{[1
]}

Inoue, Yusuke ^{[1
,2
,6
]}

Karayama, Masato ^{[1
,3
]}

Nagata, Yasuyuki ^{[4
]}

Hozumi, Hironao ^{[1
]}

Suzuki, Yuzo ^{[1
]}

Furuhashi, Kazuki ^{[1
,5
]}

Enomoto, Noriyuki ^{[1
]}

Fujisawa, Tomoyuki ^{[1
]}

Nakamura, Yutaro ^{[1
]}

Inui, Naoki ^{[1
,2
]}

Suda, Takafumi ^{[1
]}

机构：

[1] Hamamatsu Univ Sch Med, Dept Internal Med, Div 2, Hamamatsu, Japan

[2] Hamamatsu Univ Sch Med, Dept Clin Pharmacol & Therapeut, Hamamatsu, Japan

[3] Hamamatsu Univ Sch Med, Dept Clin Oncol, Hamamatsu, Japan

[4] Hamamatsu Univ Sch Med, Dept Internal Med, Div 3, Hamamatsu, Japan

[5] Hamamatsu Univ Sch Med, Dept Lab Med, Hamamatsu, Japan

[6] Hamamatsu Univ Sch Med, Div 2, 1-20-1 Handayama,Higashi Ku, Hamamatsu 4313192, Japan

来源：

JTO CLINICAL AND RESEARCH REPORTS | 2022年 / 3卷 / 01期

关键词：

Immune checkpoint inhibitors; Lung cancer; Autoimmune hemolytic anemia; Hemophagocytic lympho-histiocytosis; Case report; NIVOLUMAB;

D O I：

10.1016/j.jtocrr.2021.100263

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Various immune-related adverse events can frequently occur, which may be life-threatening if programmed death 1 or its ligand is blocked. Here, we report a rare case of concomitant autoimmune hemolytic anemia and hemophagocytic lymphohistiocytosis caused by atezolizumab plus chemotherapy in a patient with lung adenocarcinoma and autoantibodies. Dramatic and lasting tumor regression in response to only one therapy cycle was achieved. Nevertheless, this case suggests that careful management is required when using immunotherapy in patients with autoantibodies.(c) 2021 The Authors. Published by Elsevier Inc. on behalf of the International Association for the Study of Lung Cancer. This is an open access article under the CC BY-NC-ND li-cense (http://creativecommons.org/licenses/by-nc-nd/ 4.0/).

引用

页数：4

共 6 条

[1] Development and Validation of the HScore, a Score for the Diagnosis of Reactive Hemophagocytic Syndrome [J].

Fardet, Laurence ;

Galicier, Lionel ;

Lambotte, Olivier ;

Marzac, Christophe ;

Aumont, Cedric ;

Chahwan, Doumit ;

Coppo, Paul ;

Hejblum, Gilles .

ARTHRITIS & RHEUMATOLOGY, 2014, 66 (09) :2613-2620

[2] Two cases of lung cancer with hemophagocytic lymphohistiocytosis caused by immune checkpoint inhibitors [J].

Kurozumi, Atsumasa ;

Takahashi, Hidenori ;

Watanabe, Takayasu ;

Iwasaki, Yoshinobu .

THORACIC CANCER, 2021, 12 (10) :1625-1628

[3] Association of immune-related adverse events induced by nivolumab with a battery of autoantibodies [J].

Les, Inigo ;

Martinez, Mireia ;

Narro, Alicia ;

Perez, Ines ;

Sanchez, Cristina ;

Punti, Laura ;

Anaut, Pilar ;

Eguiluz, Saioa ;

Herrera, Alberto ;

Dominguez, Severina .

ANNALS OF MEDICINE, 2021, 53 (01) :762-769

[4] Pembrolizumab-induced Autoimmune Hemolytic Anemia and Hemophagocytic Lymphohistiocytosis in Non-small Cell Lung Cancer [J].

Okawa, Sachi ;

Kayatani, Hiroe ;

Fujiwara, Keiichi ;

Ozeki, Taichi ;

Takada, Kenji ;

Iwamoto, Yoshitaka ;

Minami, Daisuke ;

Sato, Ken ;

Shibayama, Takuo .

INTERNAL MEDICINE, 2019, 58 (05) :699-702

[5] Autoimmune Hemolytic Anemia as a Complication of Nivolumab Therapy [J].

Palla, Amruth R. ;

Kennedy, Devin ;

Mosharraf, Hossain ;

Doll, Donald .

CASE REPORTS IN ONCOLOGY, 2016, 9 (03) :691-697

[6] Profiling Preexisting Antibodies in Patients Treated With Anti-PD-1 Therapy for Advanced Non-Small Cell Lung Cancer [J].

Toi, Yukihiro ;

Sugawara, Shunichi ;

Sugisaka, Jun ;

Ono, Hirotaka ;

Kawashima, Yosuke ;

Aiba, Tomoiki ;

Kawana, Sachiko ;

Saito, Ryohei ;

Aso, Mari ;

Tsurumi, Kyoji ;

Suzuki, Kana ;

Shimizu, Hisashi ;

Domeki, Yutaka ;

Terayama, Keisuke ;

Nakamura, Atsushi ;

Yamanda, Shinsuke ;

Kimura, Yuichiro ;

Honda, Yoshihiro .

JAMA ONCOLOGY, 2019, 5 (03) :376-383

← 1 →